CSI Market
Sign In | Register

Biomarin Pharmaceutical Inc (BMRN) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access BMRN Annual Cash Flow →
Looking at cash flow data from Biomarin Pharmaceutical Inc through Jun 30 2025 provides insight into Jun 30 2026's financial flexibility across reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income150.29
Depreciation & amortization114.05
Amortization of Other Assets105.89
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Asset Impairment Charges64.73
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-12.33
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation119.15
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), Unrealized4.05
Impairment Of Investments-
Change Of Business Acquisition Contingent Consideration At Fair Value-
Induced Conversion Of Convertible Debt Expense-
Stock Based Compensation Capitalized-
Other Inventory Capitalized Costs-
Supplemental Accrued Expenses-
Research And Development Asset Acquired Other Than Through Business Combination Written Off220.96
Income taxes0.00
Gain (Loss) on Sale of Equity Investments0.00
Increase (Decrease) in Accounts Receivable46.01
Increase (Decrease) in Accounts Payable and Accrued Liabilities26.27
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital21.25
Other Noncash Income (Expense)5.53
Other net0.00
Payments for (Proceeds from) Other Operating Activities-256.12
Discontinued operations0.00
Net Cash flow from Operating Activities388.76
Investing Activities
Capital Expenditures-55.17
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Payments to Acquire Available-for-sale Securities, Debt0.00
Real Estate Investments0.00
Payment For Escrow Deposit-
Deposit On Purchase Of P K U Rights-
Proceeds From Sale Of Nonfinancial Assets-
Payments To Acquire Debt Securities Available For Sale Non Marketable-
Payments For Asset Acquisitions Net Of Cash Acquired-285.19
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments741.49
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Payments to Acquire Interest in Joint Venture0.00
Sale of businesses0.00
Accounts payable0.00
Payments to Acquire Notes Receivable0.00
Payments for (Proceeds from) Other Investing Activities4.97
Other Net-5,067.63
Discontinued operations0.00
Net Cash Flow from Investing Activities-4,376.35
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-65.60
Long-term debt - borrowings3,650.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock6.66
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-39.50
Other net0.00
Payment For Call Option-
Payment Of Contingent Consideration Of Acquisitions-
Payments Of Contingent Consideration-
Finance Lease Principal Payments-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities3,551.55
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow333.59
Total Cash Flow-437.67
4 historic quarters locked

Sign in to unlock the full Biomarin Pharmaceutical Inc cash flow history.

Sign In Create Free Account

About Biomarin Pharmaceutical Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001048477-26-000016

Figures are derived from filed reports and may be restated. Historical data is subject to revision.